Newsroom Bayer

June
01,
2023
| 13:59 PM Europe/Amsterdam
Phase II/III study VALOR will assess efficacy, safety and pharmacokinetics of vericiguat in pediatric patients / VALOR is the pivotal study in pediatric heart failure with vericiguat
June
01,
2023
| 08:29 AM Europe/Amsterdam
Exclusive license agreement includes rights to develop and commercialize Cedilla’s CyclinE1/CDK2 inhibitors / Assets are currently in pre-clinical development with potential to serve patients with high unmet need in underserved indications /
May
31,
2023
| 08:59 AM Europe/Amsterdam

Bayer launches unit to develop new precision health consumer products

Digital health solutions to drive transformation of everyday health:

Basel, Switzerland, May 31, 2023 – The Consumer Health Division of Bayer has launched a business unit focused on developing new Precision Health products across its range of everyday health categories. Bayer will prioritize developing products that
May
25,
2023
| 13:59 PM Europe/Amsterdam
Bayer continues to focus on advancing prostate cancer care from early to metastatic stage with darolutamide data in non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), and radium-223
May
23,
2023
| 19:07 PM Europe/Amsterdam

Bayer issues new senior bonds with a volume of 3 billion euros

NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN

Issuance consisted of three tranches with maturities between 3.25 and 10 years and was substantially oversubscribed
May
17,
2023
| 13:59 PM Europe/Amsterdam
Chinese National Medical Products Administration granted approval for a label update to extend the indication of Kerendia™ to early stages of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) and to include findings from the Phase
May
16,
2023
| 13:11 PM Europe/Amsterdam
Funding advances BBI-355, a potentially best-in-class checkpoint kinase 1 (CHK1) inhibitor, through meaningful clinical data readouts in Phase 1/2 POTENTIATE clinical trial
May
16,
2023
| 08:29 AM Europe/Amsterdam
The OCEANIC-AF (atrial fibrillation) study with asundexian is part of the Phase III OCEANIC clinical trial program enrolling more than 27,000 patients in over 40 countries / Asundexian is being evaluated as a potential improved treatment option in
May
11,
2023
| 07:29 AM Europe/Amsterdam

Slow start to the year as expected

Bayer Group business performance in the first quarter of 2023:

Group sales stable at 14.389 billion euros (Fx & portfolio adj. minus 1.1 percent)o   Accelerated normalization in glyphosate business – good price dynamics in other Crop Science unitso   New Pharmaceuticals products deliver strong growth –
May
11,
2023
| 07:29 AM Europe/Amsterdam
Four oral presentations and seven poster presentations will share insights into AskBio’s adeno-associated virus research, development and pre-clinical product progress / Breadth of research reinforces AskBio’s continued commitment to the development
May
10,
2023
| 12:59 PM Europe/Amsterdam
Collaboration will leverage Bicycle Therapeutic’s synthetic peptides for the discovery and development of multiple targeted radioconjugates of the company in oncology / Advancing the use of bicycle peptides as a novel targeting approach in

Sign up for our Newsletter

We will keep you informed about the latest news.